Skip to main content

Table 5 Overall change in monthly MHD, non-migraine headache days, and percentage reduction in monthly MHD

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

  Galcanezumab 120 mg
N = 135
Galcanezumab 240 mg
N = 135
Overall change from baseline in number of monthly MHD, mean (SD) −5.6 (0.34) −6.5 (0.33)
Overall change from baseline in monthly non-migraine headache days, mean (SD) −2.2 (0.3) −2.1 (0.3)
Overall change from baseline in number of days with acute medication use, mean (SD) −5.1 (0.4) −5.1 (0.4)
Percentage of patients who had ≥30% reduction in MHD 76.1% 80.9%
Percentage of patients who had ≥50% reduction in MHD 65.6% 73.7%
Percentage of patients who had ≥75% reduction in MHD 44.5% 52.5%
Percentage of patients who had 100% reduction in MHD 21.4% 21.8%
  1. MHD migraine headache days, SD standard deviation